DeLucia DavidChief Financial OfficerShares withheld for tax or exercise price · Sep 6, 2026
Schoeneck James AReporting ownerGrant or award · Jun 12, 2026
Kauffman MichaelReporting ownerGrant or award · Jun 12, 2026
Edwards Jeffrey LReporting ownerGrant or award · Jun 12, 2026
Ho MaykinReporting ownerGrant or award · Jun 12, 2026
About KYNTRA BIO, INC. (KYNB): stock profile, AI score and financials
KYNTRA BIO, INC. (KYNB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KYNB at 35.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,285 of 2,925 stocks — the bottom half of the AI-ranked universe. KYNB scores in the top quartile across profitability (100.0), balance sheet strength (100.0). Areas of concern include revenue growth (0.4) and revenue scale (1.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), KYNTRA BIO, INC. reports quarterly revenue of $-1.5M, net income of $12.0M, free cash flow of $-4.0M. Top institutional holders of KYNB by reported 13-F value include ARMISTICE CAPITAL, VANGUARD CAPITAL MANAGEMENT, ACADIAN ASSET MANAGEMENT, based on the most recent SEC filings. KYNB trades on the Nasdaq exchange and files with the SEC under CIK 921299. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KYNB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KYNTRA BIO, INC. directly from SEC EDGAR.